Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Identifieur interne : 000B01 ( Main/Exploration ); précédent : 000B00; suivant : 000B02Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Auteurs : Ana M. Catafau [Espagne] ; Eduardo Tolosa [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-10.
English descriptors
- KwdEn :
- Teeft :
- Abnormal, Abnormal type, Adverse events, Amersham health, Arch neurol, Atypical signs, Catafau, Caudate nucleus, Causal relationship, Challenge test, Clinical data, Clinical diagnosis, Clinical impact, Clinical management, Cocaine recognition sites, Degeneration, Diagnosis, Dopamine, Dopamine transporter, Dopaminergic, Eduardo tolosa, Essential tremor, Focal dystonia, Further investigations, Gamma cameras, High sensitivity, Imaging, Imaging result, Inconclusive, Initial diagnosis, Mild intensity, Movement disorders, Movement disorders unit, Neurol, Neurol neurosurg psychiatry, Neurologist, Neurology service, Nigrostriatal, Nigrostriatal degeneration, Nonpresynaptic, Normal scan, Normal striatal uptake, Parkinsonian, Parkinsonism, Patient management, Presynaptic, Primary somatosensory cortex, Processing protocols, Rest tremor, Severe depletion, Spect, Spect image, Spect images, Spect imaging, Spect results, Striatal, Striatal uptake, Syndrome, Therapeutic intervention, Transporter, Tremor, Uncertain parkinsonian syndromes, Uncertain parkinsonism, Visit intervals, Visual assessment.
Abstract
Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20112
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001809
- to stream Istex, to step Curation: 001700
- to stream Istex, to step Checkpoint: 000896
- to stream Main, to step Merge: 000B01
- to stream Main, to step Curation: 000B01
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><author><name sortKey="Catafau, Ana M" sort="Catafau, Ana M" uniqKey="Catafau A" first="Ana M." last="Catafau">Ana M. Catafau</name></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E7ABB9D951538A49EF1C2F044D076C52242A6699</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20112</idno><idno type="url">https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001809</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001809</idno><idno type="wicri:Area/Istex/Curation">001700</idno><idno type="wicri:Area/Istex/Checkpoint">000896</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000896</idno><idno type="wicri:doubleKey">0885-3185:2004:Catafau A:impact:of:dopamine</idno><idno type="wicri:Area/Main/Merge">000B01</idno><idno type="wicri:Area/Main/Curation">000B01</idno><idno type="wicri:Area/Main/Exploration">000B01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><author><name sortKey="Catafau, Ana M" sort="Catafau, Ana M" uniqKey="Catafau A" first="Ana M." last="Catafau">Ana M. Catafau</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut de Recerca, Hospital de Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-10">2004-10</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1175">1175</biblScope><biblScope unit="page" to="1182">1182</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E7ABB9D951538A49EF1C2F044D076C52242A6699</idno><idno type="DOI">10.1002/mds.20112</idno><idno type="ArticleID">MDS20112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>123I‐Ioflupane</term><term>SPECT</term><term>dopamine transporter</term><term>parkinsonism</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abnormal</term><term>Abnormal type</term><term>Adverse events</term><term>Amersham health</term><term>Arch neurol</term><term>Atypical signs</term><term>Catafau</term><term>Caudate nucleus</term><term>Causal relationship</term><term>Challenge test</term><term>Clinical data</term><term>Clinical diagnosis</term><term>Clinical impact</term><term>Clinical management</term><term>Cocaine recognition sites</term><term>Degeneration</term><term>Diagnosis</term><term>Dopamine</term><term>Dopamine transporter</term><term>Dopaminergic</term><term>Eduardo tolosa</term><term>Essential tremor</term><term>Focal dystonia</term><term>Further investigations</term><term>Gamma cameras</term><term>High sensitivity</term><term>Imaging</term><term>Imaging result</term><term>Inconclusive</term><term>Initial diagnosis</term><term>Mild intensity</term><term>Movement disorders</term><term>Movement disorders unit</term><term>Neurol</term><term>Neurol neurosurg psychiatry</term><term>Neurologist</term><term>Neurology service</term><term>Nigrostriatal</term><term>Nigrostriatal degeneration</term><term>Nonpresynaptic</term><term>Normal scan</term><term>Normal striatal uptake</term><term>Parkinsonian</term><term>Parkinsonism</term><term>Patient management</term><term>Presynaptic</term><term>Primary somatosensory cortex</term><term>Processing protocols</term><term>Rest tremor</term><term>Severe depletion</term><term>Spect</term><term>Spect image</term><term>Spect images</term><term>Spect imaging</term><term>Spect results</term><term>Striatal</term><term>Striatal uptake</term><term>Syndrome</term><term>Therapeutic intervention</term><term>Transporter</term><term>Tremor</term><term>Uncertain parkinsonian syndromes</term><term>Uncertain parkinsonism</term><term>Visit intervals</term><term>Visual assessment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Catafau, Ana M" sort="Catafau, Ana M" uniqKey="Catafau A" first="Ana M." last="Catafau">Ana M. Catafau</name></region><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sarre
|area= MusicSarreV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E7ABB9D951538A49EF1C2F044D076C52242A6699
|texte= Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
}}
| This area was generated with Dilib version V0.6.33. |  |